Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Joohyun Hong"'
Autor:
Hongsik Kim, Ryul Kim, Hyunji Jo, Hye Ryeon Kim, Joohyun Hong, Sang Yun Ha, Joon Oh Park, Seung Tae Kim
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and pr
Externí odkaz:
https://doaj.org/article/919143fb97924cfb80ed8df532815d79
Autor:
Joohyun Hong, Yeon Hee Park
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Although human epidermal growth factor receptor 2 (HER2)-positive breast cancer was associated with poor prognosis, it has been changed after the development of trastuzumab. There has been great progress in perioperative HER2-targeting treatment, and
Externí odkaz:
https://doaj.org/article/84be6d79fb604d218cbdc973bb983ae6
Autor:
Hyunji Jo, Joohyun Hong, Hongsik Kim, Hye Ryeon Kim, Ghee Young Kwon, Kyung A. Kang, Sung Yoon Park, Chan Kyo Kim, Byung Kwan Park, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Se Hoon Park
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposePatients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In re
Externí odkaz:
https://doaj.org/article/d54aa331e55345cfab3849aa5aec1ee0
Autor:
Hye Ryeon Kim, Soomin Ahn, Hyunji Jo, Hongsik Kim, Joohyun Hong, Jeeyun Lee, Ho-Yeong Lim, Won Ki Kang, Seung Tae Kim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTrastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burde
Externí odkaz:
https://doaj.org/article/3aabafd8b49749279f87e8b796907259
Autor:
Hongsik Kim MD, Hana Kim MD, Ryul Kim MD, PhD, Hyunji Jo MD, Hye Ryeon Kim MD, Joohyun Hong MD, PhD, Joon Oh Park MD, PhD, Young Suk Park MD, PhD, Seung Tae Kim MD, PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC).
Externí odkaz:
https://doaj.org/article/83fd42d3d7f54068817202539c732b95
Publikováno v:
Biomedicines, Vol 10, Iss 8, p 2005 (2022)
Treatment of metastatic urothelial carcinoma (mUC) after failure with platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) remains controversial. To explore the role of subsequent systemic therapy, medical records from 436 patients who
Externí odkaz:
https://doaj.org/article/772d76a670294df993ebbbcfd07e4969
Autor:
Sung Hee Lim, Jong-Mu Sun, Joohyun Hong, Dongryul Oh, Yong Chan Ahn, Man Ki Chung, Han-Sin Jeong, Young-Ik Son, Myung-Ju Ahn, Chung-Hwan Baek, Keunchil Park
Publikováno v:
The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S217-S224 (2021)
Background/Aims Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investi
Externí odkaz:
https://doaj.org/article/010453aae71043a6adf74783cb3176f2
Autor:
Joohyun Hong, Jiyun Lee, Minsuk Kwon, Ji-Yeon Kim, Jong-Won Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Publikováno v:
Diagnostics, Vol 11, Iss 2, p 370 (2021)
Genetic diagnosis for human epidermal growth factor receptor 2-negative metastatic breast cancer patients with the germline BRCA (gBRCA) mutation has been emphasized since the development of polyadenosine diphosphate-ribose polymerase inhibitors. Myr
Externí odkaz:
https://doaj.org/article/6bb7474588d047b397aba7a09d7c26cc
Autor:
Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park
Publikováno v:
Cancer Research and Treatment. 55:636-642
Purpose The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC).Materials and Methods In a prospective phase II trial, patients with cT2-T4a N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0a873a7e7c38068f96d32c842f9135
https://doi.org/10.4143/crt.2022.343
https://doi.org/10.4143/crt.2022.343
Autor:
Hye Ryeon Kim, Hyunji Jo, Hongsik Kim, Joohyun Hong, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin-Seok Ahn, Myung-Ju Ahn
Publikováno v:
Cancer Research and Treatment. 55:344-349
Leptomeningeal metastasis (LM) is a rare but fatal clinical condition with a short survival time. The incidence of LM from epidermal growth factor receptor mutant (EGFRm) non–small cell lung cancer (NSCLC) has increased due to the limited efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c04d9a2a6c5793459e47b1b2688d07d7
https://doi.org/10.4143/crt.2021.1603
https://doi.org/10.4143/crt.2021.1603